|Videos|March 22, 2023
Defining Resectability in CSCC
Following their discussions on staging and risk stratification in CSCC, key opinion leaders work to define resectability in cutaneous squamous cell carcinoma.
Advertisement
Episodes in this series
Advertisement
Related to this article
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA granted accelerated approval to RP1 plus nivolumab in anti–PD-1 therapy–pretreated advanced melanoma.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
2
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
3
Longer-Term Data Continue to Support Earlier Integration of CAR T-Cell Therapy in R/R Myeloma
4
Trastuzumab Rezetecan Elicits High ORR in HER2-High and HER2-Low Salivary Gland Carcinoma
5